Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1956 1
1961 1
1962 2
1963 6
1964 3
1965 7
1966 6
1967 4
1968 4
1969 11
1970 8
1971 6
1972 4
1973 3
1974 4
1975 6
1976 7
1977 7
1978 6
1979 3
1980 11
1981 10
1982 14
1983 14
1984 22
1985 22
1986 20
1987 23
1988 36
1989 34
1990 38
1991 30
1992 43
1993 50
1994 40
1995 57
1996 59
1997 61
1998 56
1999 52
2000 72
2001 55
2002 88
2003 80
2004 78
2005 93
2006 98
2007 105
2008 96
2009 96
2010 94
2011 88
2012 99
2013 106
2014 102
2015 131
2016 132
2017 130
2018 139
2019 121
2020 156
2021 192
2022 180
2023 148
2024 86

Text availability

Article attribute

Article type

Publication date

Search Results

3,233 results

Results by year

Filters applied: . Clear all
Page 1
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, Takashima A, Yokota M, Makiyama A, Akazawa N, Ojima H, Yuasa Y, Miwa K, Yasui H, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Hihara M, Soeda J, Misumi T, Yamamoto K, Akagi K, Ochiai A, Uetake H, Tsuchihara K, Yoshino T. Watanabe J, et al. Among authors: yamazaki k. JAMA. 2023 Apr 18;329(15):1271-1282. doi: 10.1001/jama.2023.4428. JAMA. 2023. PMID: 37071094 Free PMC article. Clinical Trial.
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer.
Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, Shirasu H, Yamazaki K, Watanabe J, Kotaka M, Hirata K, Akazawa N, Kataoka K, Sharma S, Aushev VN, Aleshin A, Misumi T, Taniguchi H, Takemasa I, Kato T, Mori M, Yoshino T. Kotani D, et al. Among authors: yamazaki k. Nat Med. 2023 Jan;29(1):127-134. doi: 10.1038/s41591-022-02115-4. Epub 2023 Jan 16. Nat Med. 2023. PMID: 36646802 Free PMC article.
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer.
Kenmotsu H, Yamamoto N, Misumi T, Yoh K, Saito H, Sugawara S, Yamazaki K, Nakagawa K, Sugio K, Seto T, Toyooka S, Date H, Mitsudomi T, Okamoto I, Yokoi K, Saka H, Okamoto H, Takiguchi Y, Takahashi T, Tsuboi M. Kenmotsu H, et al. Among authors: yamazaki k. J Clin Oncol. 2023 Dec 1;41(34):5242-5246. doi: 10.1200/JCO.23.00179. Epub 2023 Sep 1. J Clin Oncol. 2023. PMID: 37656928 Clinical Trial.
Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
Shitara K, Muro K, Watanabe J, Yamazaki K, Ohori H, Shiozawa M, Takashima A, Yokota M, Makiyama A, Akazawa N, Ojima H, Yuasa Y, Miwa K, Yasui H, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Mori I, Yamanaka K, Hihara M, Soeda J, Misumi T, Yamamoto K, Yamashita R, Akagi K, Ochiai A, Uetake H, Tsuchihara K, Yoshino T. Shitara K, et al. Among authors: yamazaki k. Nat Med. 2024 Mar;30(3):730-739. doi: 10.1038/s41591-023-02791-w. Epub 2024 Feb 12. Nat Med. 2024. PMID: 38347302 Free PMC article.
Proprioception and Geriatric Low Back Pain.
Sakai Y, Watanabe T, Wakao N, Matsui H, Osada N, Sugiura T, Morita Y, Kawai K, Ito T, Yamazaki K. Sakai Y, et al. Among authors: yamazaki k. Spine Surg Relat Res. 2022 Apr 12;6(5):422-432. doi: 10.22603/ssrr.2021-0269. eCollection 2022 Sep 27. Spine Surg Relat Res. 2022. PMID: 36348676 Free PMC article. Review.
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study).
Ando K, Nakamura Y, Kitao H, Shimokawa M, Kotani D, Bando H, Nishina T, Yamada T, Yuki S, Narita Y, Hara H, Ohta T, Esaki T, Hamamoto Y, Kato K, Yamamoto Y, Minashi K, Ohtsubo K, Izawa N, Kawakami H, Kato T, Satoh T, Okano N, Tsuji A, Yamazaki K, Yoshino T, Maehara Y, Oki E. Ando K, et al. Among authors: yamazaki k. Br J Cancer. 2023 Oct;129(6):1032-1039. doi: 10.1038/s41416-023-02378-9. Epub 2023 Aug 2. Br J Cancer. 2023. PMID: 37532830
Modulation of host glutamine anabolism enhances the sensitivity of small cell lung cancer to chemotherapy.
Kodama M, Toyokawa G, Sugahara O, Sugiyama S, Haratake N, Yamada Y, Wada R, Takamori S, Shimokawa M, Takenaka T, Tagawa T, Kittaka H, Tsuruda T, Tanaka K, Komatsu Y, Nakata K, Imado Y, Yamazaki K, Okamoto I, Oda Y, Takahashi M, Izumi Y, Bamba T, Shimizu H, Yoshizumi T, Nakayama KI. Kodama M, et al. Among authors: yamazaki k. Cell Rep. 2023 Aug 29;42(8):112899. doi: 10.1016/j.celrep.2023.112899. Epub 2023 Aug 1. Cell Rep. 2023. PMID: 37531252 Free article.
3,233 results